A major genome sequencing initiative has been launched between US biotech company Regeneron (Nasdaq: REGN), British firm GlaxoSmithKline (LSE: GSK), and the UK Biobank.
The UK Biobank is a repository of biological samples, hosted by the University of Manchester, which is available for scientific research and analysis.
Since 2006, over half a million volunteers have provided samples for the charity, which is supported by the UK’s National Health Service and funded by numerous other UK charities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze